The two new benchtop instruments, MiSeq i100 and MiSeq i100 Plus Systems, will empower customers to unlock powerful insights through an affordable, comprehensive solution that is simple to understand and use, even for those with limited NGS expertise. Room-temperature storage and shipping enable labs to sequence on demand, with no delays for thaw time, and same-day sample-to-analysis."Our customers told us they need a faster, smaller, and easy-to-use instrument, and that's what we're delivering with the MiS ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?The Zac ...

SAN DIEGO, Oct. 7, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2024 following the close of market on Monday, November 4, 2024. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The confe ...

One year ago, I wrote a bullish article on Illumina (NASDAQ: ILMN ), which I encourage readers to review as a primer for this piece. ILMN has provided a total return of 25% (including a slight benefit of the GRAIL (Edward Schneider is a managing director of Quan Management LLC. Mr. Schneider has over 30 years of investment experience, including 25 years managing technology funds in both quoted equities and venture capital. Mr. Schneider holds a CFA designation, an MBA from Thunderbird and a BA from Emory Un ...

In June 2024, GRAIL, Inc. (NASDAQ: GRAL ) was spun-off from Illumina, Inc. ( ILMN ), which had initially acquired GRAIL as recently as 2021. After struggling to defend the merger with regulatory agencies in theI'm Construction Manager for one of America's largest retailers by day, and a stock analyst by night (usually early morning). As a self-taught investor, everything I know about investing came from reading books. Mainly Benjamin Graham, Joel Greenblatt, and Tobias Carlisle, but also countless others.. ...

The market bounced back Monday after a rough week last week. We are not out of the woods yet as a huge CPI report looms on Wednesday. That sort of risk event has the power to rock financial markets. Investors looking for stocks to buy should look outside of the crowded names out there. Yes, there are opportunities outside of the Mag 7. One way to uncover these opportunities is by leaning on the Zacks Rank. Stocks with favorable Zacks Ranks have strong earnings trends which could spell profits in the future. ...

MIAMI, Sept. 9, 2024 /PRNewswire/ -- The FDA has granted approval on Illumina's TruSight Oncology Comprehensive Assay, marking a transformative milestone in cancer diagnostics. This innovative in vitro diagnostic (IVD) kit is the first of its kind, offering distributable comprehensive genomic profiling (CGP) with pan-cancer companion diagnostic claims. PreCheck Health Services is excited to introduce this test under the name SolidTumorCheck+, marking the beginning of a new phase in precision oncology and pa ...

SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's) judgment today ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL.Today's judgment confirms Illumina's longstanding view that the European Commission exceeded its authority by asserting jurisdiction over this merger. The basis for the 432 million euro fine has now been removed a ...

Core Insights - Illumina, Inc. has received FDA approval for its TruSight Oncology Comprehensive test, which analyzes over 500 genes to enhance the identification of actionable biomarkers for targeted therapies and clinical trials [1][2] - The TSO Comprehensive test is also approved as a companion diagnostic (CDx) for identifying patients with specific gene fusions, such as NTRK and RET, that may benefit from targeted treatments [2][4] Group 1: Product Development and Approval - The TSO Comprehensive test is designed to profile solid tumors and has been available in Europe since 2022 [1] - It is FDA-approved to identify adult and pediatric patients with solid tumors positive for NTRK gene fusions, which are rare but can be challenging to detect [2][3] - The test also identifies patients with RET fusion-positive non-small-cell lung cancer (NSCLC) who may benefit from Eli Lilly's RETEVMO [4] Group 2: Market Potential and Industry Trends - The global oncology CDx market was valued at $4.78 billion in 2023 and is projected to grow at a CAGR of 8.7% by 2030, driven by the increasing prevalence of cancer and the adoption of personalized medicine [7] - The need for early cancer detection tests is expected to propel market growth, improving disease management and reducing mortality [7] Group 3: Strategic Partnerships and Future Developments - Illumina's collaborations with Bayer and Eli Lilly are essential for advancing cancer diagnostics and expanding access to precision oncology [6] - The company is developing a pipeline of CDx claims through partnerships, which will enhance the TSO Comprehensive test following regulatory approvals [6] Group 4: Recent Company Performance - Illumina's stock has declined by 17.2% over the past year, while its estimated earnings for 2024 have surged nearly 94% to $3.16 per share [9] - The company has consistently beaten earnings estimates in the past four quarters, with an average surprise of 463.5% [9]

"FDA approval for TruSight Oncology Comprehensive with accompanying companion diagnostics marks an awaited milestone for our oncology customers and community," said Everett Cunningham, chief commercial officer of Illumina. "We are committed to partnering with industry leaders like Bayer and Lilly to advance cancer diagnostics and help broaden access to precision oncology for more patients."A CDx test may identify whether a patient's tumor has a specific gene change or biomarker that can be targeted by a the ...